BPRxTM060234: Lead drug candidate to treat early stages of Alzheimer’s disease

Alzheimer’s disease (AD) represents a complex class of debilitating brain diseases that mostly affects people aged 65 and older. AD is characterized by progressive loss of neurons in the hippocampus and cortex, which results in the shrinkage of brain. Basically, the brain cells required to process, store and retrieve information are killed, which is characteristic of a neurodegenerative process.

AD is a progressive neurodegenerative disorder, which killed half a million people in 2010. It is the sixth leading cause of death in US. It is estimated that by 2050, the number of people with AD may nearly triple, from 5 million to as many as 16 million, barring the development of medical breakthroughs to prevent, slow or stop the disease. Existing medications, which mostly treat symptoms, have combined sales of about $3 billion today. Any drug, which cure or manage to slow the progression of AD will be about $5-6billion dollar market.

Biotica have identified a combination of two patent-pending drug actives – BPRx060234- which simultaneously targets both amyloid plaques and tau phosphorylation, the two major causative agents of AD.